Pre-Conference Workshops (pm only) and Training Course (full day)Sunday, 14 December 2025 - PT (Pacific Time, GMT-08:00)

This session will offer perspective on what it takes to create value for biotechnology companies with a focus on early-stage (seed and Series A) therapeutics companies.

New antibody therapies span a wide range of indications with varying development costs and complexity. Partnering programs validates technology platforms, brings resources to bear, and raises funds, but dilutes ownership and long-term value. Novel antibody case studies from a range of program development stages and company sizes will be critically discussed.

The patent landscape for antibody therapeutics is rapidly evolving, with overlapping technologies and filings leading to complex freedom-to-operate issues as well as increasingly higher hurdles to obtaining patent protection. Developing robust patent estates that meet this challenging legal environment can be a key to success. Strategies for navigating this environment will be discussed.

Over the last several years, China has rapidly emerged as a leader in global drug development, now surpassing the US in the number of active clinical trials. This advancement is the result of a decade long Chinese national strategy to invest in and develop a leading biopharmaceutical industry. The implications of these changes for US biotech and biopharma will be discussed.